Effect and Cost Effectiveness of a Dyadic Empowerment-based Heart Failure Management Program for Self-care

Launched by THE UNIVERSITY OF HONG KONG · Mar 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new program called the Dyadic Empowerment-based Heart Failure Management Program (De-HF). The goal of this program is to help patients with heart failure, a condition where the heart doesn't pump blood as well as it should, manage their health better at home, especially with support from a family member or caregiver. The program uses both in-person meetings and online tools to encourage teamwork between the patient and their caregiver. Researchers want to see if this approach can improve patients' health and help them avoid returning to the hospital, while also looking at the costs involved.

To participate in this trial, you need to be 55 years or older and have had a heart failure diagnosis for at least six months. You should be living with a caregiver who helps you with your daily needs. Both you and your caregiver must be able to understand the program and have access to a smartphone or device for online meetings. If you meet these criteria, you can expect to learn new ways to manage your heart failure together with your caregiver, which might lead to better health outcomes and reduced hospital visits.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 or above
• • Confirmed medical diagnosis of Heart Failure by a cardiologist of at least 3 months
• • New York Heart Association (NYHA) Class II-IV symptoms
• • Discharged home after an admission to the recruitment setting
• • Carer co-residing with the patients in the same household
• • Carer self-identified as the primary carer for the patients
• • Both the patient and the carer having adequate cognitive ability (as indicated by an Abbreviated Test Score of \>6)
• • Have at least one Smartphone or device to access the online meetings and videos
• Exclusion Criteria:
• • Not living with primary caregiver
• • With end-stage renal disease relying on hemodialysis rather than HF medications to regulate fluid volume.